‘Osteo’ means bone. ‘Necrosis’ means death of cells or tissue in the body. Osteonecrosis of the jaw (ONJ) is a serious bone disease where there is a loss of blood supply to the bones of the jaw. This blood supply is needed to keep cells and tissues healthy and alive.
The loss of blood supply leads to exposed (uncovered) bone of the maxilla (upper jawbone) or mandible (lower jawbone). These bones should be covered by gum tissue. With ONJ, the bone is exposed through an opening in the gum tissue or because the gum tissue is completely missing.
Symptoms of ONJ may be:
ONJ may have no symptoms for weeks or months and may only be found by feeling or seeing exposed bone.
ONJ is sometimes confused with osteoradionecrosis of the jaw, which is caused by radiation therapy and is treated differently than ONJ. This article will discuss osteonecrosis of the jaw.
The exact cause of ONJ is not known, but possible causes may be:
While the exact cause of ONJ is not known, there are medications that are used to treat cancer that have been found to be related to a diagnosis of ONJ.
Some cancers affect your bones more than others, like multiple myeloma or cancers that have spread to the bone (called bone metastasis). Other health issues like diabetes can also put you at risk for ONJ. Ways that cancer can affect bones are:
Medications can be used to treat osteolytic lesions and osteosclerotic lesions caused by cancer. In some cases, these medications can cause ONJ.
There are some medications that are used to treat cancer that can increase your risk of ONJ such as bisphosphonates, denosumab, and anti-angiogenic medications.
Bisphosphonates are a group of medications that slow the breakdown of bone that happens with bone metastases or multiple myeloma (cancer of plasma cells, which enter and destroy bone). Bisphosphonates improve bone strength, slow down how quickly the bone wears away (called resorption), and lessen the build-up of unstable bone. These problems can lead to:
Currently approved bisphosphonates include:
Another medication used to slow or prevent bone breakdown and bone issues is denosumab (Xgeva®). Denosumab is a monoclonal antibody, which is a medicine that targets a specific protein or cell. Denosumab targets a protein called RANKL, which is needed for bone breakdown, but too much is made in bone metastases. By targeting RANKL, denosumab blocks or slows down bone breakdown.
Anti-angiogenesis inhibitors work by affecting a tumor's blood supply. These medications are used in many cancer treatment plans.
Most cases of ONJ are related to a dental issue, and if these are avoided, ONJ may be as well. Some things you can do to reduce your risk are:
ONJ is rare, but as people with multiple myeloma and bone metastases are living longer and being treated with medications associated with ONJ for many years, it is important to be aware of it. The medications associated with ONJ benefit patients who are at a high risk of bone issues, and there are currently no other medications that have this benefit. You must weigh the risks and benefits when deciding to use these medications. You can talk with your provider about making treatment decisions that are right for you. You should follow any directions for mouth care that you are given and report any signs or symptoms of ONJ to your provider right away.
OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem or have questions or concerns about the medication that you have been prescribed, you should consult your health care provider.
Information Provided By: www.oncolink.org | © 2025 Trustees of The University of Pennsylvania